Home > News > BioSante Presents CaP-adjuvanted Bird Flu Vaccine Data
May 23rd, 2006
BioSante Presents CaP-adjuvanted Bird Flu Vaccine Data
Abstract:
BioSante Pharmaceuticals, Inc. (Amex: BPA) today announced that Dr. Steve Bell, vice president of research and pre-clinical development, presented a case study highlighting the potential of BioVant(TM), the Company's calcium phosphate (CaP) nanoparticle-based vaccine adjuvant, in influenza virus vaccines, including H5N1 avian influenza, or bird flu.
Source:
businesswire
Related News Press |
Nanomedicine
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Good as gold - improving infectious disease testing with gold nanoparticles April 5th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Announcements
NRL charters Navy’s quantum inertial navigation path to reduce drift April 5th, 2024
Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||